• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Eli Lilly beats the Street with Q4 earnings

January 31, 2018 By Sarah Faulkner

Eli LillyShares in Eli Lilly (NYSE:LLY) fell slightly this morning even though the pharmaceutical company beat analysts’ estimates with its fourth quarter and full-year financial results.

The Indianapolis-based company swung to a net loss in the fourth quarter, posting -$1.7 billion, or $1.85 per share, on sales of $6.2 billion for the 3 months ended Dec. 31, for sales growth of 7% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were $1.14, ahead of consensus on The Street, where analysts were looking for sales of $5.9 billion.

“Lilly’s new products, including Trulicity, Taltz and Jardiance, continued to drive solid revenue growth in the fourth quarter of 2017, while we maintained flat operating expenses,” chairman & CEO David Ricks said in prepared remarks. “Momentum continues for our innovation-based strategy. We recently received approval for Taltz in the U.S. and European Union for active psoriatic arthritis, are encouraged by early use of Verzenio for breast cancer and expect further pipeline progress in 2018 in areas of significant patient need, including cancer, immunologic disorders, diabetes, neurodegeneration and pain.”

The company took a $1.9 billion hit in the fourth quarter associated with the new tax reform law, but noted that its effective tax rate for 2018 has dropped from 20.5% to 18%. In light of recently-enacted U.S. tax reform legislation, Eli Lilly increased its non-GAAP EPS guidance for 2018 to $4.81 – $4.91. The company expects to reel in between $23 billion and $23.5 billion in sales this year.

Eli Lilly’s chief finance exec told analysts that the new tax law gives the company access to more than $9 billion in cash and investments, which it plans to spend on marketed products, as well as its pipeline, according to CNBC.

For the full year, Eli Lilly posted -$204.1 million in losses on $22.87 billion in sales – up 8% from 2016.

LLY shares were trading at $82.66 apiece in mid-morning activity today, down -4%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Eli Lilly & Co.

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS